Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: Opposite effect of siRNA in combination with different drugs

Molecular Pharmacology

Volumn 68, Issue 2, 2005, Pages 372-382

  Koivusalo, Riku ^a,b   Krausz, Eberhard ^c,e   Helenius, Hans ^d   Hietanen, Sakari ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c Cenix BioScience GmbH   (Germany)

^d UNIVERSITY OF TURKU   (Finland)

^e MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; E6 SMALL INTERFERING RNA; ETOPOSIDE; GEMCITABINE; MESSENGER RNA; MITOMYCIN; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; PROTEIN; PROTEIN E6; PROTEIN P53; SMALL INTERFERING RNA; TOPOTECAN; UNCLASSIFIED DRUG;

ADDITION REACTION; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 18; MICROBIAL DEGRADATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HELA CELLS; HUMANS; ONCOGENE PROTEINS, VIRAL; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 23044502867     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.105.011189     Document Type: Article

References (31)

1. Adimoolam S and Ford JM (2003) p53 and regulation of DNA damage recognition during nucleotide excision repair. DNA Repair (Amst) 2:947-954.
2. Attardi LD (2005) The role of p53-mediated apoptosis as a crucial anti-tumor response to genomic instability: lessons from mouse models. Mutat Res 569:145-157.
3. Bernstein E, Caudy AA, Hammond SM, and Hannon GJ (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature (Lond) 409:363-366.
4. Butz K, Denk C, Ullmann A, Scheffner M, and Hoppe-Seyler F (2000) Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci USA 97:6693-6697.
5. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, and Hoppe-Seyler F (2003) siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22:5938-5945.
6. Denk C, Butz K, Schneider A, Durst M, and Hoppe-Seyler F (2001) p53 mutations are rare events in recurrent cervical cancer. J Mol Med 79:283-288.
7. El Deiry WS (2003) The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22:7486-7495.
8. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, and Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (Lond) 411:494-498.
9. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, and Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881-4886.
10. Goodwin EC and DiMaio D (2000) Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci USA 97:12513-12518.
11. Hammond SM, Bernstein E, Beach D, and Hannon GJ (2000) An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature (Lond) 404:293-296.
12. Hietanen S, Lain S, Krausz E, Blattner C, and Lane DP (2000) Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA 97:8501-8506.
13. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, and Linsley PS (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21:635-637.
14. Jiang M and Milner J (2002) Selective silencing of viral gene expression in HPVpositive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 21:6041-6048.
15. Koivusalo R and Hietanen S (2004) The cytotoxicity of chemotherapy drugs varies in cervical cancer cells depending on the p53 status. Cancer Biol Ther 3:1177-1183.
16. Koivusalo R, Krausz E, Ruotsalainen P, Helenius H, and Hietanen S (2002) Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. Cancer Res 62:7364-7371.
17. Lee JH, Kang YS, Koh JW, Park SY, Kim BG, Lee ED, Lee KH, Park KB, and Seo YL (1994) p53 gene mutation is rare in human cervical carcinomas with positive HPV sequences. Int J Gynecol Cancer 4:371-378.
18. Lipinski KS, Djeha AH, Krausz E, Lane DP, Searle PF, Mountain A, and Wrighton CJ (2001) Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53. Gene Ther 8:274-281.
19. Munger K and Howley PM (2002) Human papillomavirus immortalization and transformation functions. Virus Res 89:213-228.
20. Pirollo KF, Bouker KB, and Chang EH (2000) Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 11:419-432.
21. Schneider-Gadicke A, Kaul S, Schwarz E, Gausepohl H, Frank R, and Bastert G (1988) Identification of the human papillomavirus type 18 E6 and E6 proteins in nuclear protein fractions from human cervical carcinoma cells grown in the nude mouse or in vitro. Cancer Res 48:2969-2974.
22. Schneider-Gadicke A and Schwarz E (1986) Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. EMBO (Eur Mol Biol Organ) J 5:2285-2292.
23. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A and zur Hausen H (1985) Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature (Lond) 314:111-114.
24. Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN, and Fesik SW (2003) Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci USA 100:6347-6352.
25. Suhnel J (1996) Zero interaction response surfaces for combined-action assessment. Food Chem Toxicol 34:1151-1153.
26. Tallarida RJ (2000) Dose-response analysis, in Drug Synergism and Dose-Effect Data Analysis, pp 21-39, Chapman Hall/CRC Press, Boca Raton.
27. Thomas M and Banks L (1998) Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 17:2943-2954.
28. Vousden KH and Lu X (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2:594-604.
29. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, and Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
30. Yoshinouchi M, Yamada T, Kizaki M, Fen J, Koseki T, Ikeda Y, Nishihara T, and Yamato K (2003) In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther 8:762-768.
31. zur Hausen H (2000) Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92:690-698.